Program
Rifaximin
Also written as “Rifaximin 200 mg Tablet”, “Low Dose Rifaximin ER” and “High Dose Rifaximin ER”.
Its studies are mostly in Diarrhea · Hepatic Encephalopathy · Rosacea · Anemia, Sickle Cell · Crohn Disease, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bausch Health Companies | 161 open or running | phase 4since Apr 16, 2013 | Dec 22, 2005 | Apr 20, 2027phase 4 · NCT07285785 |
| Alfasigma | 40 open or running | phase 2since Feb 19, 2015 | Feb 19, 2015 | none ahead |
| Novartis | 10 open or running | phase 3since Sep 29, 2016 | Sep 29, 2016 | none ahead |
| Teva Pharmaceutical Industries | 10 open or running | phase 3since Jul 9, 2015 | Jul 9, 2015 | none ahead |
Also a collaborator on its studies: biorasi-llc, cromsource and parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 7 studies since Dec 22, 2005.
- Aug 24, 2008Phase 3 study in DiarrheaBausch Health Companies · NCT00742469 · 210 enrolled · Mexico
- Aug 27, 2008Phase 1 study in PharmacokineticBausch Health Companies · NCT00743912 · 24 enrolled
- Feb 27, 2012Phase 3 study in DiarrheaBausch Health Companies · NCT01543178 · 2,583 enrolled · United States, Germany, United Kingdom
- Apr 16, 20132 phase 4 studies in Hepatic EncephalopathyBausch Health Companies · NCT01842581, NCT01846663
- Jul 17, 2013Phase 2 study in Liver CirrhosisBausch Health Companies · NCT01904409 · 420 enrolled · United States, Russian Federation
- Feb 19, 2015Alfasigma's first study: phase 2 study in Vaginosis, BacterialNew to AlfasigmaAlfasigma · NCT02376972 · 392 enrolled · United States
- Jul 9, 2015Teva Pharmaceutical Industries's first study: phase 3 study in DiarrheaNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT02498418 · 739 enrolled · United States
- Sep 29, 2016Novartis's first study: phase 3 study in DiarrheaNew to NovartisNovartis · NCT02920242 · 28 enrolled · Mexico
- May 15, 2018Phase 2 study in Crohn DiseaseAlfasigma · NCT03537157 · 43 enrolled · Italy
- Jan 22, 2019Phase 4 study in Severe Hepatic ImpairmentBausch Health Companies · NCT03818672 · 5 enrolled · United States
- Mar 5, 2019Phase 2 study in RosaceaAlfasigma · NCT03864978 · 236 enrolled · Italy
- Oct 18, 2021Phase 2 study in Anemia, Sickle CellBausch Health Companies · NCT05098028 · 44 enrolled · United States, Canada, Kenya
- Oct 25, 2021Phase 2 study in RosaceaAlfasigma · NCT05150587 · 216 enrolled · United States
- Dec 2, 2025Phase 4 study in DiarrheaBausch Health Companies · NCT07285785 · 54 planned · United States
Ahead
- Apr 20, 2027Primary completion: phase 4 study in DiarrheaBausch Health Companies · NCT07285785
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Bacterial DNA-directed RNA polymerase inhibitor”ChEMBL 37, by rule
Studies
All 22 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07285785Diarrhea · United States | 4 | Recruiting | Bausch Health Companies | Apr 20, 2027 | 54 |
| NCT05150587Rosacea · United States | 2 | Completed | Alfasigma | Oct 20, 2022 | 216 |
| NCT05098028Anemia, Sickle Cell · United States, Canada, Kenya | 2 | Completed | Bausch Health Companies | Sep 4, 2023 | 44 |
| NCT03864978Rosacea · Italy | 2 | UNKNOWN | Alfasigma | Apr 2020 | 236 |
| NCT03818672Severe Hepatic Impairment · United States | 4 | Terminated | Bausch Health Companies | Feb 2, 2020 | 5 |
| NCT03537157Crohn Disease · Italy | 2 | Terminated | Alfasigma | Jul 15, 2020 | 43 |
| NCT02920242Diarrhea · Mexico | 3 | Terminated | Novartis | May 23, 2017 | 28 |
| NCT02498418Diarrhea · United States | 3 | Completed | Teva Pharmaceutical Industries | Feb 28, 2017 | 739 |
| NCT02376972Vaginosis, Bacterial · United States | 2 | Terminated | Alfasigma | Feb 2016 | 392 |
| NCT01904409Liver Cirrhosis · United States, Russian Federation | 2 | Completed | Bausch Health Companies | Jun 2015 | 420 |
| NCT01846663Hepatic Encephalopathy · United States | 4 | Terminated | Bausch Health Companies | Feb 22, 2016 | 6 |
| NCT01842581Hepatic Encephalopathy · United States | 4 | Completed | Bausch Health Companies | Dec 17, 2014 | 222 |
| NCT01543178Diarrhea · United States, Germany, United Kingdom | 3 | Completed | Bausch Health Companies | Jun 2014 | 2,583 |
| NCT00743912Pharmacokinetic | 1 | Completed | Bausch Health Companies | Oct 2008 | 24 |
| NCT00742469Diarrhea · Mexico | 3 | Completed | Bausch Health Companies | Sep 2005 | 210 |
| NCT00724126Diarrhea · United States | 3 | Completed | Bausch Health Companies | Aug 2009 | 637 |
| NCT00731679Abdominal Pain · United States, Canada | 3 | Completed | Bausch Health Companies | Aug 2009 | 623 |
| NCT00686920Hepatic Encephalopathy · United States, Canada | 3 | Completed | Bausch Health Companies | Dec 8, 2010 | 322 |
| NCT00328380Diarrhea · United States | 3 | Completed | Bausch Health Companies | Dec 2006 | 660 |
| NCT00298038Hepatic Encephalopathy | 3 | Completed | Bausch Health Companies | Aug 15, 2008 | 299 |
| NCT00269412Irritable Bowel Syndrome · United States | 2 | Completed | Bausch Health Companies | Aug 2007 | 525 |
| NCT00269399Clostridium Infections · United States | 3 | Completed | Bausch Health Companies | Dec 2008 | 237 |
How it is read
Names in the registry
- “Rifaximin”, 12 entries
- “Rifaximin 200 mg Tablet”, 1 entry
- “Low Dose Rifaximin ER”, 1 entry
- “High Dose Rifaximin ER”, 1 entry
- “Rifaximin delayed release tablets”, 1 entry
Conditions, from the studies’ own filings
- Diarrhea, 7 studies
- Hepatic Encephalopathy, 4 studies
- Rosacea, 2 studies
- Anemia, Sickle Cell, 1 study
- Crohn Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.